LYEL

insider transactions

Lyell Immunopharma, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 30d

-2.0K

0 buy · 2.0K sell

Net value · 30d

-$25.0K

$0 in · $25.0K out

Sentiment · 30d

Net selling

0% buying · 100% selling

Open-market trades · 30d

0 buy · 2.0K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Other·J
Jun 15, 26

Innovative Cellular Therapeutics Holdings Ltd

10% Owner

$0

66.5K sh
Sell·S
Jun 10, 26

David Shook

Chief Medical Officer

$25.0K

2.0K sh · $12.64

Own -9%
Grant·A
Jun 10, 26

Elizabeth G Nabel

Director

$0

9.2K sh

Own New
Grant·A
Jun 10, 26

Sumant Ramachandra

Director

$0

9.2K sh

Own New
Grant·A
Jun 10, 26

William Jl Rieflin

Director

$0

9.2K sh

Own New
Grant·A
Jun 10, 26

Cathy Friedman

Director

$0

9.2K sh

Own New
Grant·A
Jun 10, 26

Mark Bachleda

Director

$0

9.2K sh

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 15, 2026	Innovative Cellular Therapeutics Holdings Ltd	10% Owner	Other J	66.5K	—	—	$0
Jun 10, 2026	David Shook	Chief Medical Officer	Sell S	2.0K	-9%	$12.64	$25.0K
Jun 10, 2026	Elizabeth G Nabel	Director	Grant A	9.2K	New	—	$0
Jun 10, 2026	Sumant Ramachandra	Director	Grant A	9.2K	New	—	$0
Jun 10, 2026	William Jl Rieflin	Director	Grant A	9.2K	New	—	$0
Jun 10, 2026	Cathy Friedman	Director	Grant A	9.2K	New	—	$0
Jun 10, 2026	Mark Bachleda	Director	Grant A	9.2K	New	—	$0

About LYEL insider trading

This page tracks insider transactions for Lyell Immunopharma, Inc. (LYEL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.